US recession, Indian pharma and more... - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

US recession, Indian pharma and more...

Jan 8, 2008

  • Crude and gold prices continue to scale higher as investors flock to commodities as investments in wake of the slumping dollar. While crude touched the US$ 100 a barrel mark last week, the figure for gold stood at US$ 861 per ounce. It would seem that a rise in crude prices would curb the demand for oil, which in effect is not happening. Faster growing countries such as India and China continue to guzzle oil helping to keep the demand firm. Besides this, the falling dollar has made the price of oil in other currencies relatively cheaper thereby further preventing oil prices from retreating.

    While the falling dollar is just one of the various reasons (some others being geopolitical issues) that is propping up crude prices, it has been the prime catalyst for the rise of gold as the latter is seen as a safe haven in the face of a weakening dollar. Hence, while the US economy looks to be heading towards a recession in 2008 prompted by one of the worst meltdowns in the housing market, rising energy and food prices could fire up inflation thereby leading to the phenomenon called 'stagflation'.

  • A slew of weak economic reports in the US of late have sparked the downward spiral of the dollar and expectations that the Fed will further cut interest rates when it meets on January 30. For instance, the employment data released last Friday showed that the job growth slowed to the lowest since 2003. The US manufacturing index (highlighting the country's manufacturing activity), slowed to its lowest level since 2003. Not surprisingly, conditions in the housing market continued to deteriorate. In all these reports, the actual results were lower than estimates raising concerns about a possible recession in the US. Interestingly, despite this bleak outlook, the US consumer confidence rose from 87.3 to 88.6.

  • Indian pharma stocks have failed to entice investors and this can be gauged from the fact that the healthcare index has underperformed the BSE-Sensex for the past three years. The hiccups that the sector had to endure in 2007 were the sharp rupee appreciation, rise in raw material costs as imports of intermediates (used in making bulk drugs) from China got expensive and pricing pressures in the US and some of the European generic markets.

    We believe that rising competition, pricing pressure and regulatory risks besides rupee appreciation will continue to plague the sector going forward. Having said that, in the generics space, a rise in the patent expiries of drugs could provide a breather and boost revenues. The focus will shift more towards niche products, which have limited competition and consequently higher margins and biotechnology is quickly emerging as a strong focus area for a majority of leading domestic players. We believe that partnerships are likely to play a crucial role in driving growth. This could be in generics, research, new product introduction and custom manufacturing for innovator companies. For MNC companies, while new product introductions from their parents' folios will be the key to success going forward, the price of the same will most likely be subject to negotiation.

Equitymaster requests your view! Post a comment on "US recession, Indian pharma and more...". Click here!


More Views on News

How Much Money Should an Investor Set Aside for Trading? (Fast Profits Daily)

Sep 21, 2020

In this video, I'll give you a simple equation which you can use to decide how much money you can set aside for trading.

Kotak Standard Multicap Fund: Strategizing Growth with Focused Approach (Outside View)

Sep 21, 2020

PersonalFN's analysis on the features and performance of Kotak Standard Multicap Fund.

Sensex Can Go to 25,000 Before it Goes to 60,000. Are You Prepared? (Profit Hunter)

Sep 21, 2020

Am I expecting a big crack in the Sensex and what next?

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

Sundaram Bluechip Fund: Will Hold the Stable Horses (Outside View)

Sep 18, 2020

PersonalFn briefly outlines the newly launched NFO note HSBC Corporate Bond Fund.

More Views on News

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

Why am I Recommending Caution? (Fast Profits Daily)

Sep 9, 2020

This is why I have changed my short-term view on the market.

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.


Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms


Sep 21, 2020 (Close)